Copyright © 2021. Inderes Oyj. All rights reserved.

Cantargia reported its Q2 numbers this morning with an operating loss of SEK -86.6m, 3% less negative than our estimates and up 132% from last year (SEK -37.7m). The improved y/y loss was expected, as the company has initiated and applied for several studies to broaden its oncology pipeline during the quarter. The company did not change its view on the cash spending onwards and, as it guided for last quarter, the cash and cash equivalents (currently at SEK 760.7m) will last at least until the end of 2022.

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.